title: Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. fibrinogen-alginate microcapsules.
abstract: The success of cell microencapsulation technology in tissue engineering and protein delivery applications depends on the viability and functionality of the encapsulated cells, which in turn are dependent upon cell/matrix interactions. In this work, we compared the viability of cord blood-derived mesenchymal stromal cells (CB MSCs), engineered to secrete factor IX (FIX) for hemophilia treatment, and encapsulated in arginine-glycine-aspartate (RGD)-alginate versus fibrinogen-alginate microcapsules. We evaluated the effect of the biomimetic matrix on cell attachment, proliferation, and secretion of FIX. Compared with nonsupplemented alginate matrix, RGD-alginate significantly enhanced the viability of the encapsulated MSCs. Further, cells in RGD-alginate displayed distinct attachment morphology, thus suggesting that RGD-alginate can potentially be used for the encapsulation of MSCs in tissue engineering applications that require enhanced cell attachment and viability. However, our data also showed that RGD-alginate microcapsules, in contrast to fibrinogen-alginate microcapsules, did not significantly improve cell proliferation of or FIX secretion by encapsulated MSCs. Our findings suggest that evidence of cell attachment alone may not accurately predict the functionality of cells in biomimetic microcapsules.
authors.affiliation: School of Biomedical Engineering, McMaster University , Hamilton, ON , Canada.
authors.forename: Bahareh
authors.initials: B
authors.lastname: Sayyar
authors.forename: Megan
authors.initials: M
authors.lastname: Dodd
authors.forename: Leah
authors.initials: L
authors.lastname: Marquez-Curtis
authors.forename: Anna
authors.initials: A
authors.lastname: Janowska-Wieczorek
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Hortelano
mesh_terms: D000464:Alginates / Q000737:chemistry; D002214:Capsules / Q000737:chemistry / Q000378:metabolism*; D002448:Cell Adhesion; D049109:Cell Proliferation; D002470:Cell Survival; D002478:Cells, Cultured; D004339:Drug Compounding / Q000379:methods; D005109:Extracellular Matrix / Q000378:metabolism; D005164:Factor IX / Q000235:genetics / Q000378:metabolism*; D005312:Fetal Blood / Q000502:physiology*; D005340:Fibrinogen / Q000737:chemistry; D015316:Genetic Therapy; D020723:Glucuronic Acid / Q000737:chemistry; D006467:Hemophilia A / Q000235:genetics / Q000628:therapy*; D006603:Hexuronic Acids / Q000737:chemistry; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D009842:Oligopeptides / Q000737:chemistry; D023822:Tissue Engineering
chemical_list: D000464:Alginates; D002214:Capsules; D006603:Hexuronic Acids; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid; D020723:Glucuronic Acid; D005164:Factor IX; D005340:Fibrinogen